deltatrials
Completed PHASE2 NCT00958386

Safety and Efficacy Study of Panitumumab+Irinotecan in Patients Wild-Type (WT) KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy (SPECTRA)

Open, Multicenter Phase II Study to Evaluate the Efficacy and Safety of the Combination of Panitumumab With Irinotecan in Patients With Wild-Type KRAS Metastatic Colorectal Cancer Refractory to Irinotecan Based Chemotherapy

Sponsor: Amgen

Conditions Metastatic Colorectal Cancer
Interventions Panitumumab+irinotecan
Updated 5 times since 2017 Last updated: Mar 23, 2015 Started: Aug 31, 2009 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014

This PHASE2 trial investigates Metastatic Colorectal Cancer and is currently completed. Amgen leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
  • Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Data source: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Madrid, Spain